دورية أكاديمية
أعرض في EDS

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.

التفاصيل البيبلوغرافية
العنوان: Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
المؤلفون: Margonis GA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Boerner T; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY., Bachet JB; Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP) and Sorbonne Université, University Pierre and Marie Curie, Paris, France., Buettner S; Department of Surgery, Erasmus MC University Medical Centre, Rotterdam, The Netherlands., Moretto R; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy., Andreatos N; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Wang J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD., Kamphues C; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Gagniere J; Service de Chirurgie Digestive, CHU Clermont-Ferrand, Inserm, Université Clermont Auvergne, Clermont-Ferrand, France., Lonardi S; Oncology Unit 3, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Løes IM; Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University, Hospital, Bergen, Norway., Wagner D; Department of General Surgery, Medical University of Graz, Graz, Austria., Spallanzani A; Medical Oncology Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy., Sasaki K; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH., Burkhart R; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Oncology and Hemato-oncology Department, University of Milan, Milan, Italy., Pikoulis E; Third Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, 'Attikon' University General Hospital, Athens, Greece., Pawlik TM; Department of Surgery, Ohio State University, Columbus, OH., Truant S; Department of Digestive Surgery and Transplantation, CHU Lille, University Lille, Lille, France., Orlandi A; Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Pikouli A; Third Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, 'Attikon' University General Hospital, Athens, Greece., Pella N; Department of Oncology, ASUIUD University Hospital of Udine, Udine, Italy., Beyer K; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Poultsides G; Department of Surgery, Stanford University School of Medicine, Stanford, CA., Seeliger H; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Aucejo FN; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH., Kornprat P; Department of General Surgery, Medical University of Graz, Graz, Austria., Kaczirek K; Department of General Surgery, Medical University of Vienna, Vienna, Austria., Lønning PE; Department of Oncology, Haukeland University, Hospital, Bergen, Norway., Kreis ME; Department of General and Visceral Surgery, Charité Campus Benjamin Franklin, Berlin, Germany., Wolfgang CL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD., Weiss MJ; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Surgery, Zucker School of Medicine at Hofstra, Northwell Health Cancer Institute, Lake Success, NY., Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Benoist S; Department of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris-Sud University, and Paris-Sud University, Le Kremlin Bicêtre, France., D'Angelica M; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
المصدر: Annals of surgery [Ann Surg] 2023 Sep 01; Vol. 278 (3), pp. e540-e548. Date of Electronic Publication: 2022 Dec 01.
نوع المنشور: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Colorectal Neoplasms*/pathology , Liver Neoplasms*/genetics , Liver Neoplasms*/surgery , Liver Neoplasms*/secondary, Humans ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Prognosis ; Hepatectomy/methods ; Mutation
مستخلص: Objective: To investigate the clinical implications of BRAF -mutated (mut BRAF ) colorectal liver metastases (CRLMs).
Background: The clinical implications of mut BRAF status in CRLMs are largely unknown.
Methods: Patients undergoing resection for mut BRAF CRLM were identified from prospectively maintained registries of the collaborating institutions. Overall survival (OS) and recurrence-free survival (RFS) were compared among patients with V600E versus non-V600E mutations, KRAS/BRAF comutation versus mut BRAF alone, microsatellite stability status (Microsatellite Stable (MSS) vs instable (MSI-high)), upfront resectable versus converted tumors, extrahepatic versus liver-limited disease, and intrahepatic recurrence treated with repeat hepatectomy versus nonoperative management.
Results: A total of 240 patients harboring BRAF -mutated tumors were included. BRAF V600E mutation was associated with shorter OS (30.6 vs 144 mo, P =0.004), but not RFS compared with non-V600E mutations. KRAS/BRAF comutation did not affect outcomes. MSS tumors were associated with shorter RFS (9.1 vs 26 mo, P <0.001) but not OS (33.5 vs 41 mo, P =0.3) compared with MSI-high tumors, whereas patients with resected converted disease had slightly worse RFS (8 vs 11 mo, P =0.01) and similar OS (30 vs 40 mo, P =0.4) compared with those with upfront resectable disease. Patients with extrahepatic disease had worse OS compared with those with liver-limited disease (8.8 vs 40 mo, P <0.001). Repeat hepatectomy after intrahepatic recurrence was associated with improved OS compared with nonoperative management (41 vs 18.7 mo, P =0.004). All results continued to hold true in the multivariable OS analysis.
Conclusions: Although surgery may be futile in patients with BRAF -mutated CRLM and concurrent extrahepatic disease, resection of converted disease resulted in encouraging survival in the absence of extrahepatic spread. Importantly, second hepatectomy in select patients with recurrence was associated with improved outcomes. Finally, MSI-high status identifies a better prognostic group, with regard to RFS while patients with non-V600E mutations have excellent prognosis.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: J Cancer. 2013;4(4):320-2. (PMID: 23569465)
Br J Surg. 2013 May;100(6):808-18. (PMID: 23494765)
Ann Oncol. 2015 Oct;26(10):2092-7. (PMID: 26153495)
J Clin Epidemiol. 2022 Apr;144:203-205. (PMID: 34461211)
Eur Heart J. 2014 Aug 1;35(29):1925-31. (PMID: 24898551)
Cancer. 2011 Oct 15;117(20):4623-32. (PMID: 21456008)
J Clin Epidemiol. 1995 Dec;48(12):1503-10. (PMID: 8543964)
Ann Gastroenterol Surg. 2019 Jul 11;3(5):476-486. (PMID: 31549007)
Ann Surg. 2020 Jan;271(1):147-154. (PMID: 29995686)
Ann Surg Oncol. 2012 Apr;19(4):1292-301. (PMID: 21922338)
J Clin Epidemiol. 1995 Dec;48(12):1495-501. (PMID: 8543963)
Cancer. 2013 Dec 1;119(23):4137-44. (PMID: 24104864)
Surgery. 2017 Apr;161(4):909-919. (PMID: 28038862)
Gastroenterology. 2015 Jan;148(1):88-99. (PMID: 25305506)
Br J Surg. 2019 Aug;106(9):1237-1247. (PMID: 31183866)
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. (PMID: 28486044)
Cell J. 2017 Spring;19(Suppl 1):113-117. (PMID: 28580315)
J Gastrointest Surg. 2017 Jan;21(1):68-77. (PMID: 27334313)
Lancet. 2015 May 9;385(9980):1843-52. (PMID: 25862517)
Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. (PMID: 28216246)
N Engl J Med. 2019 Oct 24;381(17):1632-1643. (PMID: 31566309)
Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8. (PMID: 15383792)
JAMA Surg. 2018 Jul 18;153(7):e180996. (PMID: 29799910)
Oncologist. 2012;17(10):1225-39. (PMID: 22962059)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
المشرفين على المادة: EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
EC 2.7.11.1 (BRAF protein, human)
تواريخ الأحداث: Date Created: 20221201 Date Completed: 20230811 Latest Revision: 20240902
رمز التحديث: 20240902
مُعرف محوري في PubMed: PMC11287877
DOI: 10.1097/SLA.0000000000005771
PMID: 36453261
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000005771